• Syringin Enhances Sunitinib Efficacy via EGFR/PI3K/Akt in RC

  2026-05-09

  This study demonstrates that Syringin, a plant-derived phenylpropanoid glycoside, inhibits renal cell carcinoma (RCC) cell proliferation and enhances apoptosis by targeting the EGFR/PI3K/Akt signaling pathway. Notably, Syringin significantly increases RCC sensitivity to sunitinib, suggesting a mechanistically validated strategy to overcome drug resistance in RCC treatment.

• Pharmacological SMYD2 Inhibition Attenuates Cisplatin-Induce

  2026-05-09

  This study demonstrates that pharmacological inhibition of SMYD2, particularly with AZ505, mitigates cisplatin-induced renal fibrosis and inflammation by modulating key fibrotic and inflammatory signaling pathways. The findings highlight SMYD2 as a promising epigenetic target in chronic kidney disease (CKD) models and provide mechanistic insight for translational research using selective SMYD2 inhibitors.

• BAPTA-AM: Cell-Permeable Calcium Chelator for Precision Assa

  2026-05-08

  BAPTA-AM empowers researchers to dissect calcium signaling with unmatched spatial and temporal precision, enabling advanced live-cell imaging, apoptosis, and neuroprotection workflows. Leveraging its dual role as a calcium chelator and potassium channel blocker, BAPTA-AM stands out for experimental flexibility and reproducibility in complex cellular systems.

• METTL14-Mediated m6A Modification in Ulcerative Colitis Infl

  2026-05-07

  This study elucidates how METTL14, by modulating m6A methylation on the lncRNA DHRS4-AS1, regulates inflammatory responses in ulcerative colitis via the DHRS4-AS1/miR-206/A3AR axis. The findings highlight a mechanistic link between epigenetic RNA modification and intestinal inflammation, presenting new avenues for targeted research in inflammatory bowel disease.

• Erastin: Benchmark Ferroptosis Inducer for Oncology Research

  2026-05-07

  Erastin is a validated small molecule ferroptosis inducer that selectively triggers iron-dependent, non-apoptotic cell death in tumor cells with RAS or BRAF mutations. APExBIO’s Erastin (B1524) is widely used in cancer biology research to dissect oxidative stress pathways. This article provides structured, evidence-backed insights into Erastin’s mechanism, applications, and limitations.

• Phosphatase Inhibitor Cocktail (2 Tubes, 100X): Technical Gu

  2026-05-06

  The Phosphatase Inhibitor Cocktail (2 Tubes, 100X) is designed to maintain protein phosphorylation integrity during sample lysis and handling by inhibiting a spectrum of serine/threonine and tyrosine phosphatases. It is best suited for workflows requiring reliable preservation of phosphorylation states, such as immunoblotting and kinase activity assays, but should not be used in diagnostic or clinical applications.

• ER Stress Drives Prometastatic States in Colon Cancer Cells

  2026-05-06

  Conod et al. (2022) reveal that surviving near-lethal stress induces stable prometastatic states (PAMEs) in colon cancer cells through ER stress, nuclear reprogramming, and cytokine signaling. This paradigm shift clarifies how metastasis originates within primary tumors and identifies actionable molecular pathways for intervention.

• V5 Epitope Tag Peptide: Elevated Protein Detection Workflows

  2026-05-05

  The V5 Epitope Tag Peptide empowers precise, reproducible protein detection in multiplexed and high-throughput assays. Discover how recent antibody screening innovations and APExBIO’s high-purity formulation drive advanced Western blot, immunoprecipitation, and imaging workflows.

• Broad-Spectrum Bivalent mRNA Vaccine RQ3025 Counters SARS-Co

  2026-05-05

  A recent preclinical study introduces RQ3025, a bivalent mRNA vaccine incorporating spike mutations from diverse SARS-CoV-2 variants. RQ3025 demonstrates broad neutralizing antibody responses and Th1-biased cellular immunity in multiple animal models, highlighting its potential as a next-generation COVID-19 vaccine candidate.

• Neuroinflammation Imaging in Hepatic Encephalopathy: Bifidob

  2026-05-04

  This study uses [18F]PBR146 PET imaging to compare Bifidobacterium and fecal microbiota transplantation (FMT) for attenuating neuroinflammation in a rat model of chronic hepatic encephalopathy. The findings highlight region-specific efficacy of Bifidobacterium but limited benefit from FMT, refining our understanding of gut–brain interactions in liver disease.

• Optimizing hiPSC-Derived Platelet Production via Small Molec

  2026-05-04

  This study presents an optimized protocol for differentiating functional platelets from human induced pluripotent stem cells (hiPSCs), significantly improving yield, cost-efficiency, and process speed. By replacing traditional cytokines with targeted small molecules and refining culture conditions, the protocol advances scalable platelet manufacturing for research and therapeutic use.

• RG7388: Unlocking p53-Driven Therapy for Translational Oncol

  2026-05-03

  Explore how RG7388, a next-generation MDM2 antagonist from APExBIO, is redefining translational cancer research. This article synthesizes mechanistic advances in p53 pathway activation, highlights strategic guidance for optimizing cancer cell apoptosis induction, and discusses actionable workflow recommendations. By integrating insights from recent clinical and preclinical research—including the pivotal MDM1-p53 axis—this piece offers a forward-looking perspective on accelerating precision oncology.

• CFTRinh-172: Precision CFTR Inhibitor Workflows & Troublesho

  2026-05-02

  CFTRinh-172 empowers researchers with rapid, selective inhibition of CFTR chloride channels—ideal for dissecting epithelial transport and disease mechanisms. Leverage robust, evidence-based workflows and advanced troubleshooting strategies to unlock new insights in cystic fibrosis and secretory diarrhea research.

• Imipenem: Applied Protocols and Solutions for Antibacterial

  2026-05-02

  Imipenem, a semisynthetic thienamycin antibiotic from APExBIO, enables robust, reproducible workflows in antibacterial research, spanning both cell-based and in vivo models. This article reveals data-backed protocol strategies, advanced use-cases, and troubleshooting insights—empowering researchers to address multidrug resistance and immune modulation with confidence.

• H-89: Precision cAMP-Dependent Protein Kinase Inhibitor in B

  2026-05-01

  H-89 offers researchers a highly selective tool to dissect cAMP-dependent protein kinase (PKA) signaling, now pivotal in unraveling Wnt-induced metabolic rewiring in bone formation. Discover optimized workflows, troubleshooting strategies, and how recent breakthroughs in O-GlcNAcylation research can be practically implemented with H-89 from APExBIO.

16838 records 1/1123 page Next 12345 下5页 Last page